echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Tapentadol, a subsidiary of Renfu Pharmaceutical Holdings, obtained the tentative approval number of the US FDA

    Tapentadol, a subsidiary of Renfu Pharmaceutical Holdings, obtained the tentative approval number of the US FDA

    • Last Update: 2022-05-13
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On May 5, Humanwell Pharmaceutical announced that its holding subsidiary Humanwell Pharmaceutical US, Inc.
    (referred to as "Yichang Humanwell Pharmaceutical US Company") received the tentative approval number for tapentadol from the US FDA.

    .

    Tapentadol tablets are used to treat acute pain
    .
    Yichang Renfu Pharmaceutical USA submitted an ANDA application for tapentadol in 2020, with a cumulative R&D investment of approximately RMB 15 million

    .
    According to IQVIA statistics, the total sales of the drug (original drug) in the U.
    S.
    market in 2021 will be approximately US$190 million.
    The original drug belongs to Collegium, and manufacturers that have received tentative approval include Actavis, Alkem, Roxane, and Rhodes

    .
    There is currently no tapentadol in the domestic market.
    Anhui Xinxing Drug Development Co.
    , Ltd.
    , Jiangsu Enhua Pharmaceutical Co.
    , Ltd.
    , Jiangsu Huatai Chenguang Pharmaceutical Co.
    , Ltd.
    and the company's holding subsidiary Yichang Renfu Pharmaceutical Co.
    , Ltd.
    Conduct clinical studies of tapentadol tablets

    .

    Currently, Collegium holds two patents for tapentadol, with expiration dates on August 5, 2022 and June 27, 2025, respectively
    .
    After the above patents expire and are officially approved, Yichang Renfu Pharmaceutical US Company can market the tapentadulo tablets that have obtained the ANDA approval number this time

    .

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.